Promising Publication: The Novel Schizophrenia Treatment Gaining Traction

Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on the phase II clinical data for KarXT, published in the New England Journal of Medicine.

To read more, see Journal Publication Brings Good News for Novel Schizophrenia Treatment.

Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2023 MJH Life Sciences

All rights reserved.